Adell Harriman & Carpenter Inc. Boosts Position in Amgen Inc. $AMGN

Adell Harriman & Carpenter Inc. lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 7.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 22,008 shares of the medical research company’s stock after buying an additional 1,609 shares during the quarter. Adell Harriman & Carpenter Inc.’s holdings in Amgen were worth $7,204,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Robeco Institutional Asset Management B.V. increased its holdings in shares of Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after acquiring an additional 43,884 shares during the period. Curtis Advisory Group LLC bought a new position in Amgen in the fourth quarter worth about $1,669,000. Jones Financial Companies Lllp raised its holdings in Amgen by 18.2% in the third quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock worth $10,888,000 after purchasing an additional 6,115 shares in the last quarter. Lockheed Martin Investment Management Co. purchased a new stake in shares of Amgen during the third quarter valued at about $2,624,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Amgen by 8.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 591,891 shares of the medical research company’s stock valued at $167,032,000 after buying an additional 47,958 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Get Amgen alerts:

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a planned CFO transition, with Peter Griffith retiring and Thomas Dittrich returning to the company to succeed him. A well-telegraphed succession plan can reduce uncertainty around finance leadership and is typically viewed as a stability signal. AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH
• Neutral Sentiment: Amgen also named an analyst report in the news flow, along with Piper Sandler trimming its price target while keeping an Overweight rating. That suggests continued long-term optimism, but the target cut is a modest headwind rather than a major catalyst. Amgen (AMGN) Gets Price Target Cut at Piper Sandler Despite Long-Term Growth Optimism
• Negative Sentiment: Separately, Amgen’s kidney disease drug Tavneos faced renewed scrutiny in Japan, where partner Kissei urged doctors to use caution and avoid starting new patients amid safety and regulatory concerns. Headlines like this can pressure sentiment because they raise questions about the product’s commercial trajectory and safety profile. Amgen Japanese Partner Urges Caution On Tavneos Use

Wall Street Analyst Weigh In

AMGN has been the topic of a number of analyst reports. Truist Financial lifted their price objective on shares of Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a research report on Friday, May 1st. Royal Bank Of Canada increased their target price on shares of Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. TD Cowen restated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Citigroup increased their price objective on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $356.15.

Check Out Our Latest Research Report on Amgen

Amgen Stock Performance

Shares of AMGN stock opened at $330.75 on Wednesday. The business has a fifty day moving average of $347.53 and a 200 day moving average of $343.86. Amgen Inc. has a 1 year low of $267.83 and a 1 year high of $391.29. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The firm has a market capitalization of $178.50 billion, a price-to-earnings ratio of 23.02, a price-to-earnings-growth ratio of 3.26 and a beta of 0.44.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, research analysts expect that Amgen Inc. will post 22.37 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 3.0%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is 70.15%.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.85% of the company’s stock.

About Amgen

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Featured Articles

• Five stocks we like better than Amgen
• HIVE Weaponizes Power for an AI Pivot
• A Deep Dive Into NVIDIA’s Latest Portfolio Moves
• Brady Corp Wires Up a Massive AI-Powered Breakout
• Why Home Depot’s Sell-Off Could Become a Huge Opportunity

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.